| CAS NO: | 1185239-64-8 |
| 包装: | 1mg |
| 市场价: | 5216元 |
| Cas No. | 1185239-64-8 |
| 别名 | 斯利潘托 d9 |
| Canonical SMILES | OC(C(C([2H])([2H])[2H])(C([2H])([2H])[2H])C([2H])([2H])[2H])/C=C/C1=CC(OCO2)=C2C=C1 |
| 分子式 | C14H9D9O3 |
| 分子量 | 243.3 |
| 溶解度 | Chloroform: soluble |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Stiripentol-d9 is intended for use as an internal standard for the quantification of stiripentol by GC- or LC-MS. Stiripentol is a third-generation antiepileptic compound.1 It is a positive allosteric modulator of GABAA receptors, potentiating GABA-mediated activation to a greater extent in receptors expressing α3 subunits and to a lower extent in those containing β1 or ε subunits.2 It also inhibits GABA reuptake in vitro and increases the release of GABA in neonatal rat hippocampal slices.1,3 Stiripentol (500 μM) inhibits lactate dehydrogenase (LDH), blocking both lactate-to-pyruvate and pyruvate-to-lactate conversions by human LDH1 and LDH5.4 Formulations containing stiripentol have been used in the adjunctive treatment of seizures associated with Dravet syndrome. |1. Luszczki, J.J. Third-generation antiepileptic drugs: Mechanisms of action, pharmacokinetics and interactions. Pharmacol. Rep. 61(2), 197-216 (2009).|2. Fisher, J.L. The anti-convulsant stiripentol acts directly on the GABAA receptor as a positive allosteric modulator. Neuropharmacology 56(1), 190-197 (2009).|3. Quilichini, P.P., Chiron, C., Ben-Ari, Y., et al. Stiripentol, a putative antiepileptic drug, enhances the duration of opening of GABAA-receptor channels. Epilepsia 47(4), 704-716 (2006).|4. Sada, N., Lee, S., Katsu, T., et al. Targeting LDH enzymes with a stiripentol analog to treat epilepsy. Science 347(6228), 1362-1367 (2015). |
m.cnreagent.com